1 | Etanercepet, Rituximab, Abatacept, Tocilizumab, Sarilumab (Kevzara (TN)) | 4件: Abatacept Abatacept, Rituximab, Sarilumab (Kevzara), Tocilizumab | 4件: Tocilizumab
Tocilizumab
,
Rituximab
,
Abatacept
,
Sarilumab
(Kevzara (TN)) 💬
| 4件: CD80 CD80, CD86, IL6R, MS4A1 💬
| 25件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Rheumatoid arthritis, Systemic lupus erythematosus, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Viral protein interaction with cytokine and cytokine receptor, Virion - Adenovirus 💬 | 1件: 46 46 💬
|
2 | Kevzara | 1件: Sarilumab Sarilumab (Kevzara) | 1件: Sarilumab
Sarilumab
(Kevzara (TN)) 💬
| 1件: IL6R IL6R 💬
| 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 2件: 41 41, 46 💬
|
3 | Kevzara ® | 1件: Sarilumab Sarilumab (Kevzara) | 1件: Sarilumab
Sarilumab
(Kevzara (TN)) 💬
| 1件: IL6R IL6R 💬
| 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 41 41 💬
|
4 | SARILUMAB (Kevzara (TN)) | 1件: Sarilumab Sarilumab (Kevzara) | 1件: Sarilumab
Sarilumab
(Kevzara (TN)) 💬
| 1件: IL6R IL6R 💬
| 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 5件: 41 41, 46, 84, 107, 271 💬
|
5 | Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA] | 1件: Sarilumab Sarilumab (Kevzara) | 1件: Sarilumab
Sarilumab
(Kevzara (TN)) 💬
| 1件: IL6R IL6R 💬
| 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 💬
|
6 | Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA]_#1 | 1件: Sarilumab Sarilumab (Kevzara) | 1件: Sarilumab
Sarilumab
(Kevzara (TN)) 💬
| 1件: IL6R IL6R 💬
| 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 84 84 💬
|
7 | Sarilumab SAR153191 (Kevzara (TN)) | 1件: Sarilumab Sarilumab (Kevzara) | 1件: Sarilumab
Sarilumab
(Kevzara (TN)) 💬
| 1件: IL6R IL6R 💬
| 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 41 41 💬
|
8 | Sarilumab SAR153191 (REGN88) (Kevzara (TN)) | 1件: Sarilumab Sarilumab (Kevzara) | 1件: Sarilumab
Sarilumab
(Kevzara (TN)) 💬
| 1件: IL6R IL6R 💬
| 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 2件: 46 46, 107 💬
|